Related Experiment Video

Updated: Feb 25, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.2K

Novel therapeutic agents in the management of brain metastases

Vyshak A Venur1, Manmeet S Ahluwalia

  • 1aDivision of Hematology and Oncology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa bTaussig Cancer Institute, Cleveland Clinic cBurkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA.

Current Opinion in Oncology
|August 9, 2017
PubMed
Abstract

Insights

Novel therapies, including tyrosine kinase inhibitors and immunotherapies, show promise for treating brain metastases from lung cancer, breast cancer, and melanoma. Further research is needed to improve patient survival rates.

Area of Science:

  • Neuro-oncology
  • Medical Oncology
  • Clinical Pharmacology

Background:

  • Brain metastases represent a significant challenge in cancer care, often associated with poor prognosis.
  • Current management strategies are evolving with the advent of novel systemic therapies.

Purpose of the Study:

  • To review emerging therapeutic agents for brain metastases in clinical development.
  • To highlight recent findings from clinical trials, publications, and conferences.

Main Methods:

  • Systematic review of recent clinical trials and scientific literature.
  • Analysis of data from national and international oncology conferences.

Main Results:

  • Several novel systemic treatments demonstrate significant intracranial and extracranial activity in clinical trials.
  • Agents targeting common primary tumors (lung, breast, melanoma) are a focus.
  • Tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and immunotherapies (anti-CTLA-4, anti-PD-1) show promise.

Conclusions:

  • Newer TKIs, monoclonal antibodies, and immunotherapies exhibit encouraging intracranial activity in select brain metastases patients.
  • Further research is essential to optimize therapeutic strategies and enhance survival for patients with brain metastases.

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.9K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
683
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K